CNBC reports J&J is the fourth drugmaker backed by the Trump administration’s Covid-19 vaccine program Operation Warp Speed to enter late-stage testing.
The trial will enroll up to 60,000 volunteers across 215 locations in the U.S. and other countries, according to the National Institute of Allergy and Infectious Diseases.